Skip to main content

Table 1 Patient group characteristics

From: A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data

Variable

Concurrent mental and opioid use disorder

Opioid use disorder only

Standardized differences (sd)

 

N = 48,679 (87.0)

7245 (13.0)

 

Age

  

0.3

 15 to 24

8.727 (17.9)

1514 (20.9)

 

 25 to 34

16,148 (33.2)

2859 (39.5)

 

 35 to 44

10,712 (22.0)

1383 (19.1)

 

 45 to 54

8812 (18.1)

989 (13.7)

 

 55 to 64

3348 (6.9)

338 (4.7)

 

 +65+

932 (1.9)

162 (2.2)

 

Sex

  

0.2

 +Male

30,654 (63.0)

5575 (77.0)

 

 Female

18,025 (37.0)

1670 (23.1)

 

Geography

  

0.2

 +Southern urban

37,887 (77.8)

5209 (71.9)

 

 Northern rural

2240 (4.6)

593 (21.0)

 

 Northern urban

4533 (9.3)

761 (10.5)

 

 Southern rural

4016 (8.2)

682 (9.4)

 

Income

  

0.0

 +5

5532 (11.5)

734 (10.4)

 

 4

7014 (14.6)

1078 (15.2)

 

 3

8690 (18.1)

1282 (18.1)

 

 2

10,886 (22.6)

1613 (22.7)

 

 1 (lowest)

16,020 (33.3)

2388 (33.7)

 

HIV positive

390 (0.8)

21 (0.3)

0.1

Deep-tissue infection

1584 (3.3)

92 (1.3)

0.1

All-cause mortality

2485 (5.1)

227 (3.1)

0.1

*One year continuous OAT

8757 (37.6)

903 (35.7)

0.2

*Mean days buprenorphine (SD)

55.0 (167.8)

34.8 (121.8)

< .0001

*Mean days methadone (SD)

356.8 (441.0)

344.6 (409.8)

< .0.042

  1. sd standardized difference, SD standard deviation
  2. +Reference group
  3. *Ontario Drug Benefit plan subgroup analysis (n = 28,500)